Outlook Therapeutics is preparing for the U.S. commercial launch of LYTENAVA after the FDA approved it as the only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The company estimates the U.S. anti-VEGF retina market at about $8.5 billion annually and targets more than $500 million in peak annual LYTENAVA sales by 2030, with first-year post-launch revenue projected at $50 million to $75 million and pricing expected below $500 per vial. It plans to hire roughly 50 field personnel, including about 30 customer-facing commercial employees and 20 field reimbursement staff, and expects to submit a permanent HCPCS code application by the end of the third quarter. The company reported an adjusted quarterly net loss of $10.9 million and had $11.2 million in cash as of June 30, with a subsequent $55 million stock-and-warrant offering expected to provide about $51.1 million in net proceeds to fund the launch and working capital.
OUTLOOK THERAPEUTICS INCFDA approval enables LYTENAVA launch in wet AMD market
Advanced Micro Devices Inc